Bone infections are stubborn. When antibiotics and surgery fail to eradicate the pathogens lurking deep within marrow cavities, physicians face a daunting challenge. Chronic refractory osteomyelitis—defined as bone infection persisting or recurring despite appropriate surgical intervention and targeted antibiotic therapy—represents one of the most frustrating conditions in orthopedic and infectious disease medicine. For the estimated 50,000 Americans hospitalized annually with this condition, the consequences can be devastating: progressive bone destruction, pathological fractures, sepsis, and all too often, amputation.
Enter hyperbaric oxygen therapy (HBOT). While the therapy has garnered headlines for its off-label use in wellness circles and sports recovery, its role in treating chronic refractory osteomyelitis is firmly established in the medical mainstream. The FDA cleared HBOT as an adjunctive treatment for this indication decades ago, and Medicare has covered it since 1977. Yet many patients—and even some clinicians—remain unaware of this evidence-based option when conventional treatments reach their limits.
The Oxygen Paradox: Why Standard Care Falls Short
Osteomyelitis creates a cruel physiological trap. The infection triggers inflammation, which compromises local blood supply. Ischemic bone tissue becomes hypoxic, with tissue oxygen tensions dropping below the 30 mmHg threshold necessary for effective leukocyte bacterial killing. Without adequate oxygen, neutrophils and macrophages cannot generate the oxidative burst required to destroy pathogens—particularly the increasingly common methicillin-resistant Staphylococcus aureus (MRSA) and polymicrobial infections that dominate chronic cases.
Standard therapy follows a familiar algorithm: surgical debridement to remove necrotic bone and infected tissue, followed by weeks or months of intravenous antibiotics tailored to culture results. Yet even with optimal surgical technique and appropriate antimicrobial selection, cure rates for chronic refractory osteomyelitis hover around 50% without adjunctive measures. Biofilms—structured communities of bacteria encased in protective extracellular matrices—form on devitalized bone surfaces, rendering antibiotics ineffective and providing a reservoir for persistent infection.
How HBOT Breaks the Cycle
Hyperbaric oxygen therapy addresses the fundamental pathophysiology that perpetuates chronic bone infection. During a typical session, patients breathe 100% oxygen at pressures of 2.0 to 2.5 atmospheres absolute (ATA) for 90 to 120 minutes. This increases plasma oxygen concentration ten- to fifteen-fold, allowing oxygen to diffuse into ischemic tissues far beyond what hemoglobin transport alone can achieve.
The mechanisms are multifactorial and well-characterized in the literature:
Enhanced leukocyte function sits at the core of HBOT’s antimicrobial effect. Research published in Undersea and Hyperbaric Medicine demonstrates that neutrophil oxidative killing capacity increases proportionally with tissue oxygen tension, peaking at approximately 150 mmHg—levels achievable only in a hyperbaric environment. This restored immune function proves particularly crucial against anaerobic and facultative organisms that thrive in the hypoxic niches of infected bone.
Antibiotic potentiation represents another critical benefit. Aminoglycosides, fluoroquinolones, and certain beta-lactams demonstrate enhanced bacterial killing in oxygen-rich environments. HBOT improves antibiotic penetration into poorly vascularized tissues while simultaneously increasing bacterial susceptibility through oxidative stress mechanisms.
Angiogenesis and tissue repair complete the therapeutic picture. HBOT stimulates vascular endothelial growth factor (VEGF) production and promotes fibroblast proliferation, accelerating the formation of healthy granulation tissue and improving blood supply to previously ischemic bone. This neovascularization not only supports ongoing antimicrobial defenses but also facilitates bone remodeling and fracture healing.
The Evidence Base: From Case Series to Clinical Guidelines
The FDA’s clearance of HBOT for chronic refractory osteomyelitis rests on decades of clinical research, though the evidence landscape reflects the challenges of studying a condition that defies large-scale randomized trials.
A landmark 2025 case series published in the Journal of Bone and Joint Infection followed 11 patients with post-traumatic osteomyelitis who had failed standard surgical and antibiotic therapy. After adjunctive HBOT—typically 40 to 60 sessions over several months—all patients achieved infection resolution with mean follow-up exceeding three years. The study emphasized the importance of combining HBOT with aggressive surgical debridement and organism-specific antibiotics, noting that HBOT functions as an adjunct rather than a standalone treatment.
Systematic reviews paint a consistent picture. A comprehensive analysis cited by UnitedHealthcare in their 2026 coverage policy examined 14 retrospective studies, 6 prospective cohort studies, and 20 case reports encompassing 460 patients. While acknowledging substantial heterogeneity and the limitations of predominantly pre-2000 data, reviewers concluded that adjunctive HBOT improves cure rates from approximately 50% to 85–86% when combined with surgery and antibiotics. This magnitude of benefit—halving treatment failure rates—represents a clinically meaningful advance for a condition with few alternative options.
The Undersea and Hyperbaric Medical Society (UHMS) includes refractory osteomyelitis among its 14 approved indications for HBOT, noting that candidates include patients who have failed at least one surgical procedure intended to eradicate disease or who have experienced recurrence after apparently successful treatment. The society’s clinical practice guidelines emphasize early referral, as prolonged infection duration correlates with worse outcomes and increased risk of irreversible bone damage.
Patient Selection and Treatment Protocols
Not every patient with osteomyelitis requires HBOT. The therapy is specifically indicated for chronic refractory cases—those persisting beyond six months or recurring after appropriate initial treatment. Acute hematogenous osteomyelitis in children, when diagnosed early and treated promptly with antibiotics, rarely requires hyperbaric intervention.
Ideal candidates include patients with:
- Documented chronic osteomyelitis following appropriate surgical debridement
- Persistent or recurrent infection despite targeted antibiotic therapy
- Compromised local vascularity (radiation-induced injury, diabetic microangiopathy, or severe trauma)
- Involvement of poorly perfused bone (mandible, sternum, or small bones of the hands and feet)
- Infection with resistant organisms or polymicrobial flora
Standard protocols involve 90- to 120-minute sessions at 2.0 to 2.5 ATA, typically five days per week for 4 to 6 weeks. Some protocols extend to 60 sessions for extensive involvement or particularly resistant infections. Treatment occurs in monoplace (single-patient) or multiplace (multiple patients) chambers, with the latter allowing medical attendance during sessions for patients requiring complex care.
Safety, Costs, and Access Considerations
HBOT for chronic refractory osteomyelitis carries a favorable safety profile, though it is not without risks. Barotrauma to ears or sinuses affects approximately 5% of patients, while oxygen toxicity seizures occur in roughly 1 in 10,000 sessions—typically self-limited and without lasting sequelae when managed appropriately. The 2025 FDA safety letter emphasizing fire risks and proper chamber operation serves as an important reminder that HBOT must be administered by trained personnel in accredited facilities.
Financial access has improved substantially. Medicare Part B covers HBOT for chronic refractory osteomyelitis under National Coverage Determination 20.29, reimbursing 80% of approved costs after the annual deductible. Most major private insurers follow Medicare’s lead, though prior authorization is typically required. For uninsured patients, out-of-pocket costs range from $200 to $600 per session depending on geographic location and facility type—substantial, but often less expensive than the alternative of prolonged hospitalization, repeated surgeries, or amputation.
The Bottom Line
Chronic refractory osteomyelitis represents a genuine therapeutic success story for hyperbaric oxygen therapy—one where FDA clearance, robust clinical evidence, and decades of clinical experience align. Unlike the wellness industry’s more speculative applications of HBOT, this indication addresses a well-defined pathophysiological problem with measurable outcomes.
For patients facing the grim prospect of persistent bone infection, HBOT offers a legitimate adjunctive option that can tip the balance toward cure. The key lies in appropriate patient selection, integration with comprehensive surgical and antimicrobial care, and realistic expectations: HBOT is not a magic bullet, but rather a powerful tool that, deployed correctly, can rescue patients when standard therapy falls short.
As research continues to refine protocols and identify optimal candidates, HBOT’s role in osteomyelitis management appears secure—a rare instance where the therapy’s regulatory status, scientific rationale, and clinical utility stand on equally solid ground.